Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

License To Fill: Pipeline Top AstraZeneca Priority Under Brennan

Executive Summary

AstraZeneca's plans to bolster its product pipeline include further efforts to tap external technology sources, according to CEO David Brennan

You may also be interested in...



Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space

Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows

AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space

AstraZeneca Clinical Setbacks Add To Pipeline Woes

AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline

Related Content

UsernamePublicRestriction

Register

PS047296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel